This year, gene-editing technology was customized to fix mutations in a single patient’s genes for the first time.

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...

CRISPR, the gene-editing technology which won its creators the 2020 Nobel Prize for Chemistry, is most well-known for its ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...

Discover how scientists engineered goldenberry plants to grow 35% shorter than usual, making them suitable for large-scale ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

For years, Yale researchers David Breslow and Mustafa Khokha have worked together with a similar challenge in their ...

Higher yields, greater resilience to climatic changes or diseases—the demands on crop plants are constantly growing. To ...

Goldenberries taste like a cross between pineapple and mango, pack the nutritional punch of a superfood, and are increasingly ...

You've probably heard about the gene-editing technology CRISPR. The massive biotech breakthrough, which has emerged in the last decade, has mainly been touted for the ways it will let scientists edit ...

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the most oversold biotech stocks to invest in. Following the company’s third ...